NAV

Tildipirosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tildipirosin
DrugBank Accession Number
DB11470
Background

Tildipirosin is a veterinary antibiotic.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 734.032
Monoisotopic: 733.524116258
Chemical Formula
C41H71N3O8
Synonyms
  • Tildipirosin
  • Tildipirosina
  • Tildipirosine
  • Tildipirosinum
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Tildipirosin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Tildipirosin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Tildipirosin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Tildipirosin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Tildipirosin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Zuprevo

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / Hexoses / O-glycosyl compounds / Piperidines / Oxanes / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Cyclic ketones / Trialkylamines
show 10 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Azacycle / Carbonyl group
show 23 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
S795AT66JB
CAS number
328898-40-4
InChI Key
HNDXPZPJZGTJLJ-UEJFNEDBSA-N
InChI
InChI=1S/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/m1/s1
IUPAC Name
(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-[2-(piperidin-1-yl)ethyl]-15-[(piperidin-1-yl)methyl]-1-oxacyclohexadeca-11,13-diene-2,10-dione
SMILES
[H][C@@]1(O[C@H]2[C@@H](CCN3CCCCC3)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@H](CN3CCCCC3)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]2C)O[C@H](C)[C@@H](O)[C@@H]([C@H]1O)N(C)C

References

General References
  1. Menge M, Rose M, Bohland C, Zschiesche E, Kilp S, Metz W, Allan M, Ropke R, Nurnberger M: Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle). J Vet Pharmacol Ther. 2012 Dec;35(6):550-9. doi: 10.1111/j.1365-2885.2011.01349.x. Epub 2011 Dec 21. [Article]
  2. Andersen NM, Poehlsgaard J, Warrass R, Douthwaite S: Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides. Antimicrob Agents Chemother. 2012 Nov;56(11):6033-6. doi: 10.1128/AAC.01250-12. Epub 2012 Aug 27. [Article]
  3. Poehlsgaard J, Andersen NM, Warrass R, Douthwaite S: Visualizing the 16-membered ring macrolides tildipirosin and tilmicosin bound to their ribosomal site. ACS Chem Biol. 2012 Aug 17;7(8):1351-5. doi: 10.1021/cb300105p. Epub 2012 May 14. [Article]
  4. Michael GB, Eidam C, Kadlec K, Meyer K, Sweeney MT, Murray RW, Watts JL, Schwarz S: Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica. J Antimicrob Chemother. 2012 Jun;67(6):1555-7. doi: 10.1093/jac/dks076. Epub 2012 Mar 7. [Article]
  5. Rose M, Menge M, Bohland C, Zschiesche E, Wilhelm C, Kilp S, Metz W, Allan M, Ropke R, Nurnberger M: Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae. J Vet Pharmacol Ther. 2013 Apr;36(2):140-53. doi: 10.1111/j.1365-2885.2012.01397.x. Epub 2012 Apr 15. [Article]
  6. Gautier-Bouchardon AV, Ferre S, Le Grand D, Paoli A, Gay E, Poumarat F: Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France. PLoS One. 2014 Feb 4;9(2):e87672. doi: 10.1371/journal.pone.0087672. eCollection 2014. [Article]
  7. Rose M, Pridmore A, Shaw A, Wilhelm C, Menge M, Kilp S, Ropke R, Nurnberger M: A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs. J Vet Pharmacol Ther. 2016 Jun;39(3):277-86. doi: 10.1111/jvp.12277. Epub 2015 Nov 5. [Article]
  8. Dieste-Perez L, Fraile L, de Miguel MJ, Barberan M, Blasco JM, Munoz PM: Studies on a suitable antibiotic therapy for treating swine brucellosis. J Vet Pharmacol Ther. 2015 Aug;38(4):357-64. doi: 10.1111/jvp.12189. Epub 2014 Nov 21. [Article]
  9. Dickson LC: Performance characterization of a quantitative liquid chromatography-tandem mass spectrometric method for 12 macrolide and lincosamide antibiotics in salmon, shrimp and tilapia. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15;967:203-10. doi: 10.1016/j.jchromb.2014.07.031. Epub 2014 Jul 27. [Article]
  10. Emmerich IU: [New drugs for horses and production animals in 2011]. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2012 Oct 17;40(5):301-8. [Article]
ChemSpider
30790722
RxNav
1306059
ChEMBL
CHEMBL3039509
ZINC
ZINC000096941865

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0548 mg/mLALOGPS
logP3.75ALOGPS
logP4.46Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.68Chemaxon
pKa (Strongest Basic)10.05Chemaxon
Physiological Charge3Chemaxon
Hydrogen Acceptor Count10Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area132.24 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity206.76 m3·mol-1Chemaxon
Polarizability83.58 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000t-1000009500-f3c130dea26bf39e3955
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0000002900-88377a6078f6f2017c3c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01q9-1200017900-24a8e45215ca91baa374
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0560-2100967500-67a00b0641dfe661a8d6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9600000000-edf7ab9357d4b39942b7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014l-4000249100-f606f4e2308e998df35d
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-250.17378
predicted
DeepCCS 1.0 (2019)
[M+H]+251.8975
predicted
DeepCCS 1.0 (2019)
[M+Na]+258.21555
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 19:01 / Updated at February 21, 2021 18:53